Your browser doesn't support javascript.
loading
CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS.
Tian, Ren-Rong; Zhang, Ming-Xu; Zhang, Lin-Tao; Zhang, Peng; Ma, Jian-Ping; Liu, Mingyue; Devenport, Martin; Zheng, Pan; Zhang, Xiao-Liang; Lian, Xiao-Dong; Ye, Mei; Zheng, Hong-Yi; Pang, Wei; Zhang, Gao-Hong; Zhang, Li-Guo; Liu, Yang; Zheng, Yong-Tang.
Afiliação
  • Tian RR; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
  • Zhang MX; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China; Kunming College of Life Science, University of Chinese Ac
  • Zhang LT; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
  • Zhang P; Center for Cancer and Immunology Research and Division of Pathology, Children's Research Institute, Children's National Medical Center, Washington DC 20010, USA.
  • Ma JP; CAS Key Laboratory for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Liu M; Center for Cancer and Immunology Research and Division of Pathology, Children's Research Institute, Children's National Medical Center, Washington DC 20010, USA.
  • Devenport M; OncoImmune, Inc., Rockville, MD, USA.
  • Zheng P; Center for Cancer and Immunology Research and Division of Pathology, Children's Research Institute, Children's National Medical Center, Washington DC 20010, USA; OncoImmune, Inc., Rockville, MD, USA.
  • Zhang XL; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
  • Lian XD; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China; Kunming College of Life Science, University of Chinese Ac
  • Ye M; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China; Kunming College of Life Science, University of Chinese Ac
  • Zheng HY; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
  • Pang W; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
  • Zhang GH; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
  • Zhang LG; CAS Key Laboratory for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: liguozhang@ibp.ac.cn.
  • Liu Y; Center for Cancer and Immunology Research and Division of Pathology, Children's Research Institute, Children's National Medical Center, Washington DC 20010, USA; OncoImmune, Inc., Rockville, MD, USA. Electronic address: yaliu@cnmc.org.
  • Zheng YT; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China; Kunming College of Life Science, University of Chinese Ac
Antiviral Res ; 157: 9-17, 2018 09.
Article em En | MEDLINE | ID: mdl-29983395
ABSTRACT
Chronic immune activation and systemic inflammation are underlying causes of acquired immunodeficiency syndrome (AIDS). Products of virus replication and microbial translocation, co-infection or opportunistic pathogens, and danger-associated molecular patterns have been reported to contribute to chronic immune activation and inflammation in human immunodeficiency virus type-1/simian immunodeficiency virus (HIV-1/SIV) infection or other disease. To develop new strategies and therapies for HIV-1/AIDS, we tested if the CD24 and Fc fusion protein (CD24Fc), which interacts with danger-associated molecular patterns and sialic acid binding Ig-like lectin to attenuate inflammation, can protect Chinese rhesus macaques (ChRMs) with SIV infection. We found that CD24Fc treatment decreased weight loss, wasting syndrome, intractable diarrhea, and AIDS morbidity and mortality, while it was well tolerated by SIV-infected animals. Corresponding to the elimination of intractable diarrhea, CD24Fc significantly reduced the expression of IL-6 and indoleamine 2, 3-dioxygenase-1 in peripheral blood mononuclear cell and inflammation in the ileum, colon and rectum based on the reduction of inflammatory cells, pathological scores and expression of inflammatory cytokines. Furthermore, although CD24Fc did not restore CD4+ T cell number or significantly change T cell subsets or CD4+ T cell activation, it maintained low levels of plasma soluble CD14, CD8+ T cell activation, viral load and proviral load in the peripheral blood mononuclear cells and marrow. These results suggested that CD24Fc confers protection to SIV-infected ChRMs against progression to AIDS. It was also implied that CD24Fc may be a potential therapeutic approach for the control of HIV-1/AIDS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Fragmentos Fc das Imunoglobulinas / Síndrome de Imunodeficiência Adquirida dos Símios / Antígeno CD24 / Fatores Imunológicos Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Fragmentos Fc das Imunoglobulinas / Síndrome de Imunodeficiência Adquirida dos Símios / Antígeno CD24 / Fatores Imunológicos Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article